Immunic (NASDAQ:IMUX) announces the completion of enrollment of 210 subjects in a Phase 2 clinical trial, EMPhASIS, evaluating lead candidate IMU-838 in patients with relapsing-remitting multiple sclerosis (RRMS).
The primary endpoint is the cumulative number of
combined unique active MRI lesions at week 24 compared to placebo. The
estimated primary completion date is November 2020.
The company says IMU-838 is
an orally available, next-generation immune modulator that dampens the
immune response by inhibiting an enzyme called dihydroorotate
dehydrogenase (DHODH) that plays a key role in intracellular metabolism
of activated immune cells.
https://seekingalpha.com/news/3505144-immunic-completes-enrollment-mid-stage-study-ms-candidate-imuminus-838
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.